SNP genetic polymorphisms of MDR-1, CYP1A2 and CYPB11 genes in four canine breeds upon toxicological evaluation.
10.4142/jvs.2015.16.3.273
- Author:
Rosa GAGLIARDI
1
;
Silvia LLAMBI
;
M Victoria ARRUGA
Author Information
1. Genetic Area, Faculty of Veterinary, University of La Republica, Montevideo, C.P. 11600, Uruguay.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
dog;
drug resistance;
pharmacogenomics;
SNP polymorphisms
- MeSH:
Animals;
Aryl Hydrocarbon Hydroxylases/*genetics/metabolism;
Cytochrome P-450 CYP1A2/*genetics/metabolism;
Dogs/*genetics/metabolism;
P-Glycoprotein/*genetics/metabolism;
*Polymorphism, Single Nucleotide;
Steroid Hydroxylases/*genetics/metabolism
- From:Journal of Veterinary Science
2015;16(3):273-280
- CountryRepublic of Korea
- Language:English
-
Abstract:
The fields of pharmacogenetics and pharmacogenomics have become increasingly promising regarding the clinical application of genetic data to aid in prevention of adverse reactions. Specific screening tests can predict which animals express modified proteins or genetic sequences responsible for adverse effects associated with a drug. Among the genetic variations that have been investigated in dogs, the multidrug resistance gene (MDR) is the best studied. However, other genes such as CYP1A2 and CYP2B11 control the protein syntheses involved in the metabolism of many drugs. In the present study, the MDR-1, CYP1A2 and CYP2B11 genes were examined to identify SNP polymorphisms associated with these genes in the following four canine breeds: Uruguayan Cimarron, Border Collie, Labrador Retriever and German Shepherd. The results revealed that several SNPs of the CYP1A2 and CYP2B11 genes are potential targets for drug sensitivity investigations.
